scholarly article | Q13442814 |
P819 | ADS bibcode | 2016PLoSO..1156213S |
P356 | DOI | 10.1371/JOURNAL.PONE.0156213 |
P932 | PMC publication ID | 4880220 |
P698 | PubMed publication ID | 27224423 |
P50 | author | Emma S. McBryde | Q39990382 |
Jack Stone | Q60164968 | ||
Peter Vickerman | Q61912869 | ||
Margaret E Hellard | Q85903750 | ||
Matthew Hickman | Q37828999 | ||
Heidi E Drummer | Q38323304 | ||
P2093 | author name string | Natasha K Martin | |
Nick Scott | |||
P2860 | cites work | Hepatitis C virus therapeutic development: in pursuit of "perfectovir". | Q38374284 |
Hepatitis C: the next 25years | Q39156863 | ||
Can needle and syringe programmes and opiate substitution therapy achieve substantial reductions in hepatitis C virus prevalence? Model projections for different epidemic settings | Q39559418 | ||
Novel adenovirus-based vaccines induce broad and sustained T cell responses to HCV in man. | Q39866377 | ||
People who inject drugs in prison: HIV prevalence, transmission and prevention | Q41458000 | ||
Use of contingency management incentives to improve completion of hepatitis B vaccination in people undergoing treatment for heroin dependence: a cluster randomised trial | Q42225127 | ||
The impact of needle and syringe provision and opiate substitution therapy on the incidence of hepatitis C virus in injecting drug users: pooling of UK evidence. | Q42602432 | ||
A randomised controlled trial of financial incentives to increase hepatitis B vaccination completion among people who inject drugs in Australia | Q43419623 | ||
Estimating the prevalence of ex-injecting drug use in the population. | Q43428423 | ||
Cost-effectiveness analysis of a hypothetical hepatitis C vaccine compared to antiviral therapy | Q43517228 | ||
Assessing IDU prevalence and health consequences (HCV, overdose and drug-related mortality) in a primary care trust: implications for public health action | Q44412085 | ||
Disparity in market prices for hepatitis C virus direct-acting drugs | Q45340234 | ||
Cost-effectiveness of hepatitis C virus antiviral treatment for injection drug user populations | Q45363548 | ||
Hepatitis B vaccine uptake among injecting drug users in England 1998 to 2004: is the prison vaccination programme driving recent improvements? | Q47573169 | ||
The outcome of a rapid hepatitis B vaccination programme in a methadone treatment clinic. | Q52295844 | ||
New Expensive Treatments for Hepatitis C Infection | Q57255675 | ||
Potential cost-effectiveness of a preventive hepatitis C vaccine in high risk and average risk populations in Canada | Q57695969 | ||
Can antiviral therapy for hepatitis C reduce the prevalence of HCV among injecting drug user populations? A modeling analysis of its prevention utility | Q57701087 | ||
Hepatitis B vaccination in prisons: the Catalonian experience | Q72779415 | ||
Look behind bars for key to control of STDs | Q74082675 | ||
Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews | Q24630669 | ||
Global epidemiology and genotype distribution of the hepatitis C virus infection | Q27001240 | ||
Hepatitis C Infection Among Injecting Drug Users in England and Wales (1992-2006): There and Back Again? | Q27488973 | ||
Global epidemiology of hepatitis C virus infection | Q27860799 | ||
A hepatitis C virus (HCV) vaccine comprising envelope glycoproteins gpE1/gpE2 derived from a single isolate elicits broad cross-genotype neutralizing antibodies in humans | Q28488268 | ||
Vaccination of chimpanzees against infection by the hepatitis C virus | Q29615899 | ||
Potential impact of vaccination on the hepatitis C virus epidemic in injection drug users | Q33824723 | ||
Dancing with chemical formulae of antivirals: A panoramic view (Part 2). | Q34038340 | ||
Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. | Q34320498 | ||
Pertussis circulation has increased T-cell immunity during childhood more than a second acellular booster vaccination in Dutch children 9 years of age. | Q34364307 | ||
Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression | Q34787367 | ||
Recombinant hepatitis B vaccine (Engerix-B): a review of its immunogenicity and protective efficacy against hepatitis B. | Q35109126 | ||
HCV treatment rates and sustained viral response among people who inject drugs in seven UK sites: real world results and modelling of treatment impact. | Q35535844 | ||
Adherence to hepatitis B virus vaccination at syringe exchange sites | Q36274505 | ||
Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies | Q36346436 | ||
Economic evaluation of delivering hepatitis B vaccine to injection drug users | Q36789998 | ||
Combination interventions to prevent HCV transmission among people who inject drugs: modeling the impact of antiviral treatment, needle and syringe programs, and opiate substitution therapy | Q37042425 | ||
Meta-regression of hepatitis C virus infection in relation to time since onset of illicit drug injection: the influence of time and place | Q37306146 | ||
Interventions to reduce HIV transmission related to injecting drug use in prison | Q37354455 | ||
Hepatitis C virus treatment for prevention among people who inject drugs: Modeling treatment scale-up in the age of direct-acting antivirals | Q37601315 | ||
Challenges to the development of vaccines to hepatitis C virus that elicit neutralizing antibodies | Q38234934 | ||
P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
P6216 | copyright status | copyrighted | Q50423863 |
P433 | issue | 5 | |
P407 | language of work or name | English | Q1860 |
P304 | page(s) | e0156213 | |
P577 | publication date | 2016-05-25 | |
P1433 | published in | PLOS One | Q564954 |
P1476 | title | The Potential Impact of a Hepatitis C Vaccine for People Who Inject Drugs: Is a Vaccine Needed in the Age of Direct-Acting Antivirals? | |
P478 | volume | 11 |
Q61813267 | A Novel Vaccine Strategy Employing Serologically Different Chimpanzee Adenoviral Vectors for the Prevention of HIV-1 and HCV Coinfection |
Q61958644 | Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission |
Q59351582 | Approaches, Progress, and Challenges to Hepatitis C Vaccine Development |
Q39333862 | Designing an HCV vaccine: a unique convergence of prevention and therapy? |
Q57161290 | HIV, HCV and HBV: A Review of Parallels and Differences |
Q39238761 | Hepatitis C treatment as prevention: evidence, feasibility, and challenges |
Q89725315 | Hepatitis C vaccine: 10 good reasons for continuing |
Q57162382 | Hepatitis C virus genotype 3: clinical features, current and emerging viral inhibitors, future challenges |
Q97418726 | Hepatitis C virus vaccine design: focus on the humoral immune response |
Q38635796 | Hepatitis C: Review of the Epidemiology, Clinical Care, and Continued Challenges in the Direct Acting Antiviral Era. |
Q59350606 | Mathematical modeling of hepatitis c virus (HCV) prevention among people who inject drugs: A review of the literature and insights for elimination strategies |
Q92951971 | Modeling indicates efficient vaccine-based interventions for the elimination of hepatitis C virus among persons who inject drugs in metropolitan Chicago |
Q52315227 | Opioids, Hepatitis C Virus Infection, and the Missing Vaccine. |
Q52597010 | Research gaps in viral hepatitis. |
Q45324462 | The Rationale for a Preventative HCV Virus-Like Particle (VLP) Vaccine |
Q63246174 | Toward DNA-Based T-Cell Mediated Vaccines to Target HIV-1 and Hepatitis C Virus: Approaches to Elicit Localized Immunity for Protection |
Search more.